• 1
    Carrero JJ, Stenvinkel P. Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 2009; 4(Suppl. 1): S4955.
  • 2
    Carrero JJ, Park SH, Axelsson J, Lindholm B, Stenvinkel P. Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: a dreadful triad. Semin Dial 2009; 22: 3816.
  • 3
    Khoueiry G, Waked A, Goldman M et al. Dietary intake in hemodialysis patients does not reflect a heart healthy diet. J Ren Nutr 2011; 21: 43847.
  • 4
    Arslan Y, Kiziltan G. Nutrition-related cardiovascular risk factors in hemodialysis patients. J Ren Nutr 2010; 20: 18592.
  • 5
    Huang X, Stenvinkel P, Qureshi AR et al. Essential polyunsaturated fatty acids, inflammation and mortality in dialysis patients. Nephrol Dial Transplant 2012. DOI: 10.1093/ndt/gfs132. PMID: 22565059.
  • 6
    Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol 2003; 14: 159.
  • 7
    Ntambi JM, Miyazaki M. Regulation of stearoyl-CoA desaturases and role in metabolism. Prog Lipid Res 2004; 43: 91104.
  • 8
    Bjermo H, Riserus U. Role of hepatic desaturases in obesity-related metabolic disorders. Curr Opin Clin Nutr Metab Care 2010; 13: 7038.
  • 9
    Brown JM, Chung S, Sawyer JK et al. Inhibition of stearoyl-coenzyme A desaturase 1 dissociates insulin resistance and obesity from atherosclerosis. Circulation 2008; 118: 146775.
  • 10
    Warensjo E, Ohrvall M, Vessby B. Fatty acid composition and estimated desaturase activities are associated with obesity and lifestyle variables in men and women. Nutr Metab Cardiovasc Dis 2006; 16: 12836.
  • 11
    Bjermo H, Iggman D, Kullberg J et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr 2012; 95: 100312.
  • 12
    Attie AD, Krauss RM, Gray-Keller MP et al. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res 2002; 43: 1899907.
  • 13
    Riserus U, Arnlov J, Berglund L. Long-term predictors of insulin resistance: role of lifestyle and metabolic factors in middle-aged men. Diabetes Care 2007; 30: 292833.
  • 14
    Vessby B, Aro A, Skarfors E, Berglund L, Salminen I, Lithell H. The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters. Diabetes 1994; 43: 13537.
  • 15
    Petersson H, Basu S, Cederholm T, Riserus U. Serum fatty acid composition and indices of stearoyl-CoA desaturase activity are associated with systemic inflammation: longitudinal analyses in middle-aged men. Br J Nutr 2008; 99: 11869.
  • 16
    Petersson H, Lind L, Hulthe J, Elmgren A, Cederholm T, Riserus U. Relationships between serum fatty acid composition and multiple markers of inflammation and endothelial function in an elderly population. Atherosclerosis 2009; 203: 298303.
  • 17
    Warensjo E, Sundstrom J, Vessby B, Cederholm T, Riserus U. Markers of dietary fat quality and fatty acid desaturation as predictors of total and cardiovascular mortality: a population-based prospective study. Am J Clin Nutr 2008; 88: 2039.
  • 18
    Warensjo E, Riserus U, Gustafsson IB, Mohsen R, Cederholm T, Vessby B. Effects of saturated and unsaturated fatty acids on estimated desaturase activities during a controlled dietary intervention. Nutr Metab Cardiovasc Dis 2008; 18: 68390.
  • 19
    Chong MF, Hodson L, Bickerton AS et al. Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 d of high-carbohydrate feeding. Am J Clin Nutr 2008; 87: 81723.
  • 20
    Corpeleijn E, Feskens EJ, Jansen EH et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia 2006; 49: 2392401.
  • 21
    Choi JY, Yoon YJ, Choi HJ et al. Dialysis modality-dependent changes in serum metabolites: accumulation of inosine and hypoxanthine in patients on haemodialysis. Nephrol Dial Transplant 2011; 26: 130413.
  • 22
    Chuang CK, Lin SP, Chen HH et al. Plasma free amino acids and their metabolites in Taiwanese patients on hemodialysis and continuous ambulatory peritoneal dialysis. Clin Chim Acta 2006; 364: 20916.
  • 23
    Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899911.
  • 24
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499502.
  • 25
    Detsky AS, McLaughlin JR, Baker JP et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr 1987; 11: 813.
  • 26
    Qureshi AR, Alvestrand A, Danielsson A et al. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 1998; 53: 77382.
  • 27
    Boberg M, Croon LB, Gustafsson IB, Vessby B. Platelet fatty acid composition in relation to fatty acid composition in plasma and to serum lipoprotein lipids in healthy subjects with special reference to the linoleic acid pathway. Clin Sci (Lond) 1985; 68: 5817.
  • 28
    Smedman AE, Gustafsson IB, Berglund LG, Vessby BO. Pentadecanoic acid in serum as a marker for intake of milk fat: relations between intake of milk fat and metabolic risk factors. Am J Clin Nutr 1999; 69: 229.
  • 29
    Kotronen A, Seppanen-Laakso T, Westerbacka J et al. Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum. Obesity (Silver Spring) 2010; 18: 93744.
  • 30
    Warensjo E, Rosell M, Hellenius ML, Vessby B, De Faire U, Riserus U. Associations between estimated fatty acid desaturase activities in serum lipids and adipose tissue in humans: links to obesity and insulin resistance. Lipids Health Dis 2009; 8: 37.
  • 31
    Vessby B, Uusitupa M, Hermansen K et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. Diabetologia 2001; 44: 3129.
  • 32
    Becher W, Pearson M. Riksmaten. Kostvanor och näringsintag i Sverige. (National Survey of Dietary Habits and Nutrient Intake in Sweden). Uppsala: Livsmedelsverket (National Food Administration), 1997–1998.
  • 33
    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496509.
  • 34
    Miyazaki M, Flowers MT, Sampath H et al. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab 2007; 6: 48496.
  • 35
    Savransky V, Jun J, Li J et al. Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. Circ Res 2008; 103: 117380.
  • 36
    Menghini R, Menini S, Amoruso R et al. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 2009; 136: 66372.
  • 37
    Liu X, Miyazaki M, Flowers MT et al. Loss of Stearoyl-CoA desaturase-1 attenuates adipocyte inflammation: effects of adipocyte-derived oleate. Arterioscler Thromb Vasc Biol 2010; 30: 318.
  • 38
    Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 301525.
  • 39
    Nguyen MT, Favelyukis S, Nguyen AK et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007; 282: 3527992.
  • 40
    Brown JM, Chung S, Sawyer JK et al. Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 2430.
  • 41
    Chmielewski M, Carrero JJ, Qureshi AR et al. Temporal discrepancies in the association between the apoB/apoA-I ratio and mortality in incident dialysis patients. J Intern Med 2009; 265: 70816.
  • 42
    Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793808.
  • 43
    An WS, Kim SE, Kim KH et al. Comparison of fatty acid contents of erythrocyte membrane in hemodialysis and peritoneal dialysis patients. J Ren Nutr 2009; 19: 26774.
  • 44
    Heimburger O. Statins and lipid-lowering strategies in PD. Contrib Nephrol 2012; 178: 10610.
  • 45
    Andersson G, Bergquist-Poppen M, Bergstrom J, Collste LG, Hultman E. Glucose absorption from the dialysis fluid during peritoneal dialysis. Scand J Urol Nephrol 1971; 5: 779.
  • 46
    Astrup A, Dyerberg J, Elwood P et al. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010? Am J Clin Nutr 2011; 93: 6848.
  • 47
    Chajes V, Jenab M, Romieu I et al. Plasma phospholipid fatty acid concentrations and risk of gastric adenocarcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Am J Clin Nutr 2011; 94: 130413.
  • 48
    Sjogren P, Sierra-Johnson J, Gertow K et al. Fatty acid desaturases in human adipose tissue: relationships between gene expression, desaturation indexes and insulin resistance. Diabetologia 2008; 51: 32835.
  • 49
    Saadatian-Elahi M, Slimani N, Chajes V et al. Plasma phospholipid fatty acid profiles and their association with food intakes: results from a cross-sectional study within the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2009; 89: 33146.
  • 50
    Brown JM, Rudel LL. Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery. Curr Opin Lipidol 2010; 21: 1927.